Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNEUROPHARMACOLOGY

Use of Trifluoroperazine Isolates a [3H]Ifenprodil Binding Site in Rat Brain Membranes with the Pharmacology of the Voltage-Independent Ifenprodil Site onN-Methyl-d-aspartate Receptors Containing NR2B Subunits

Linda L. Coughenour and Bridget M. Barr
Journal of Pharmacology and Experimental Therapeutics January 2001, 296 (1) 150-159;
Linda L. Coughenour
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bridget M. Barr
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The use of trifluoroperazine in a well washed rat brain membrane preparation revealed [3H]ifenprodil binding to a single high affinity state with the pharmacology ofN-methyl-d-aspartate (NMDA) receptors containing NR2B subunits. Inhibition of [3H]ifenprodil binding in the presence of trifluoroperazine by 10 NR1a/NR2B selective agents was highly correlated with their inhibition at rat NR1a/NR2B receptors expressed in Xenopus ooctyes and [3H]TCP binding to rat brain NR2B subunit containing NMDA receptors but not with their inhibition of [3H]DTG binding. Allosteric interactions with polyamines, Mg2+, Zn2+, glutamate, glycine, and their antagonists were consistent with NMDA receptors with NR2B subtype pharmacology. The rank order of polyamine inhibition was spermine > spermidine > 1,5-(diethylamino)piperidine > arcaine > agmatine > putrescine. Both spermidine and MgCl2 shifted the inhibition curve of ifenprodil to the right in a parallel manner, but Mg2+ did not appear to be additive to spermidine. Glutamate increased and glycine decreased the binding. Conversely, CPP decreased the binding, and MDL 105,519 increased the binding in an agonist reversible manner. The increase with MDL 105,519 and glutamate appeared to be additive as did the decrease with glycine and CPP. Changes in the buffer pH between 6.5 and 8.0 did not affect the affinity of NR2B agents. Cirazoline but not clonidine inhibited the binding. MK-801 and agents from various other pharmacological classes did not significantly inhibit [3H]ifenprodil binding. [3H]Ifenprodil binding in the presence of trifluoroperazine appears to be selective for the voltage-independent ifenprodil site on NMDA receptors containing the NR2B subunit.

Footnotes

  • Send reprint requests to: Dr. Linda L. Coughenour, Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Rd., Ann Arbor, MI 48105. E-mail:Linda.Coughenour{at}wl.com

  • Preliminary findings in this study were presented at the Meeting for the Society for Neuroscience (Coughenour et al., 1998; Barr et al., 1999).

  • Abbreviations:
    NMDA
    N-methyl-d-aspartate
    TCP
    N-[1-(2-thienyl)cyclohexyl]piperidine
    MK-801
    (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (dizolcipine)
    GBR-12909
    1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride
    eliprodil
    (±)-α-(4-chlorophenyl)-4-[4-fluorophenyl)]-1-piperidineethanol
    PPBP
    4-phenyl-1-(4-penylbutyl)piperidine
    CP-101,606
    (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol
    CPP
    (±)-3-(2-carboxypiperazin-4-yl)-propyl-l-phosphonic acid
    Co 101314
    4-[1-(4phenylbutyl)piperidine-4-yl]phenyl
    Co 101313
    4-(4-methoxyphenyl)-1-(4-phenylbutyl)piperidine
    Co 101244
    1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine-4-ol
    MDL 105,519
    (Z)-2-carboxy-4,6-dichloroindole-3-(2′-phenyl-2′-carboxy)-ene
    DEAP
    1,5-(diethylamino)piperidine
    DTG
    1,3-di(2-tolyl)guanidine
    NR
    NMDA receptor
    • Received July 18, 2000.
    • Accepted August 15, 2000.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 296 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 296, Issue 1
1 Jan 2001
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Use of Trifluoroperazine Isolates a [3H]Ifenprodil Binding Site in Rat Brain Membranes with the Pharmacology of the Voltage-Independent Ifenprodil Site onN-Methyl-d-aspartate Receptors Containing NR2B Subunits
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNEUROPHARMACOLOGY

Use of Trifluoroperazine Isolates a [3H]Ifenprodil Binding Site in Rat Brain Membranes with the Pharmacology of the Voltage-Independent Ifenprodil Site onN-Methyl-d-aspartate Receptors Containing NR2B Subunits

Linda L. Coughenour and Bridget M. Barr
Journal of Pharmacology and Experimental Therapeutics January 1, 2001, 296 (1) 150-159;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleNEUROPHARMACOLOGY

Use of Trifluoroperazine Isolates a [3H]Ifenprodil Binding Site in Rat Brain Membranes with the Pharmacology of the Voltage-Independent Ifenprodil Site onN-Methyl-d-aspartate Receptors Containing NR2B Subunits

Linda L. Coughenour and Bridget M. Barr
Journal of Pharmacology and Experimental Therapeutics January 1, 2001, 296 (1) 150-159;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Experimental Procedures
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CVN424, a novel GPR6 inverse agonist for Parkinson's disease
  • Methylone Brain Concentrations and Pharmacodynamic Effects
  • Oxysterols and Ethanol
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics